281.49
price down icon1.12%   -3.20
after-market After Hours: 282.00 0.51 +0.18%
loading

Why is Alnylam Pharmaceuticals Inc (ALNY) Stock down?

We've noticed a 8.47% decline in Alnylam Pharmaceuticals Inc (ALNY) stock during the 2024-08-30 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
15 Feb, 2024:

Alnylam Pharmaceuticals Inc (ALNY) stock plummeted by 10.19% due to concerns arising from a key clinical trial design change, overshadowing a minor Q4 revenue miss.

  • Q4 Results and Financial Performance: Alnylam reported Q4 total revenue of $439.7 million, reflecting a 31% increase year over year, slightly below analysts' average estimate of $442.9 million. The company posted a net loss of $137.9 million, or $1.10 per share (GAAP), with a non-GAAP net loss of $96.6 million, or $0.77 per share.
  • *Concerns Over Clinical Trial Design**: Investor worries stemmed from Alnylam's announcement of an updated statistical analysis plan and revised timing for its Helios-B phase 3 study evaluating vutrisiran in treating ATTR-CM. Changes include focusing on outcome measures in overall and monotherapy populations, tweaking secondary endpoints, and extending the trial by up to three months.
  • Investor Reaction and Analysis: Investors interpreted the revised trial plan as a potential lack of management confidence in the Helios-B results, leading to the stock's sharp decline. While conservative investors may shy away due to the inherent risks, more aggressive investors could view the dip as a buying opportunity, considering the company's solid sales growth and management's confidence in the trial's outcome.
14 Sep, 2023:

Alnylam Pharmaceuticals' stock fell sharply by 8.78% to $193.06, as a split advisory panel recommended FDA approval for their heart disease treatment, Onpattro, but with conditions. The panel indicated its potential usefulness for patients unresponsive to Pfizer's tafamidis, causing a drop of 8.8% in Alnylam's stock to $193.06 below its 50-day moving average.

https://www.investors.com/news/technology/alnylam-stock-tumbles-on-dashed-hopes-of-rivaling-pfizer-in-heart-disease-treatment/?src=A00220

$551.71
price down icon 0.21%
$113.94
price down icon 0.06%
$205.99
price down icon 4.87%
$54.72
price down icon 0.91%
$361.40
price up icon 2.44%
Cap:     |  Volume (24h):